#1 Clinical Trials Search in Europe

LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V)

Clinical trials are investigating LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V) in children with acute bronchitis. These studies aim to assess clinical efficacy and safety, and to see whether it may help reduce unnecessary antibiotic use.

Table of contents

Trial overview

The clinical trial with NCT ID 2025-520845-61-00 is studying LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V) in children with acute bronchitis.[1] The study is designed to assess whether the treatment can help in this condition and whether it is safe to use in the target group.[1]

Study design and phase

This is an interventional study, which means the researchers give a treatment and then measure the results.[1] It is described as double-blind, randomized, and placebo-controlled.[1] These terms mean that treatment groups are assigned by chance, and neither the participants nor the researchers know who receives the study treatment or the placebo during the trial.[1] The trial is listed as Phase 3 and has an enrollment of 56 participants.[1]

Who can participate

The target population is pediatric patients, meaning children.[1] The trial data do not provide more detailed age limits or other eligibility rules.[1] The study focuses on children who have acute bronchitis.[1]

What is being measured

The main endpoint is the efficacy of the investigational product based on the Bronchitis Severity Score.[1] Efficacy means how well the treatment works in the study.[1] The Bronchitis Severity Score is used to measure how severe the bronchitis symptoms are.[1]

The brief summary also says the study is looking at safety and at whether the treatment may help reduce inappropriate antibiotic use in acute bronchitis in children.[1] This shows that the trial is not only about symptom relief, but also about better treatment use in practice.[1]

Why this study matters

Acute bronchitis in children can lead to treatment decisions that are not always ideal, including antibiotic use when it may not be needed.[1] This trial is trying to learn whether LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V) can be a useful option for this condition in a controlled research setting.[1] Because the study is placebo-controlled, it can help compare the study treatment with a look-alike treatment that has no active drug.[1]

Trial details at a glance

Item Information
Trial ID 2025-520845-61-00
Status Authorised
Condition Acute bronchitis
Population Pediatric patients
Design Double-blind, randomized, placebo-controlled
Phase Phase 3
Enrollment 56
Main endpoint Efficacy based on the Bronchitis Severity Score
Trial ID Phase Condition studied Status Enrollment
2025-520845-61-00 Phase 3 Acute bronchitis Authorised 56

FAQ

  • What condition is being studied with LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V)? The trial is studying acute bronchitis. This is a short-term inflammation of the airways that can cause coughing and chest discomfort.
  • Who can take part in the trial? The study is designed for pediatric patients, which means children. The trial data do not give more detailed age limits.
  • What is the main goal of the study? The main goal is to check how well the investigational product works and whether it is safe. The study also looks at whether it can help reduce inappropriate antibiotic use in acute bronchitis.
  • What phase is this trial? The trial is listed as Phase 3. This phase usually tests a treatment in a larger group to learn more about how well it works.
  • What result is being measured? The main result is efficacy based on the Bronchitis Severity Score. This score is used to measure how bad the bronchitis symptoms are.

Ongoing Clinical Trials on LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V)

  • Study on the Effectiveness of Elixirium Thymi Compositum for Treating Acute Bronchitis in Children

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Hungary

Glossary

  • Acute bronchitis: A short-lasting illness where the airways in the lungs become inflamed, often causing cough and breathing discomfort.
  • Pediatric patients: Children who are taking part in a medical study.
  • Double-blind: A study design where neither the participants nor the study team knows who gets the study treatment and who gets the placebo.
  • Randomized: Participants are placed into study groups by chance, not by choice.
  • Placebo: A look-alike treatment that does not contain the active study drug.
  • Phase 3: A later stage of clinical research that tests a treatment in a larger group of people.
  • Interventional study: A study where researchers give a treatment and then measure the results.
  • Bronchitis Severity Score: A scoring system used to measure how severe bronchitis symptoms are.
  • Efficacy: How well a treatment works under study conditions.
  • Safety: Information about how well a treatment is tolerated and whether it causes problems.

References